Skip to main content
European Commission logo
Enterprise Europe Network

Non-antibiotic technology for combating bacteria in e.g. agriculture and horticulture, animal husbandry, veterinary medicine, animal feed production and similar industries


Profile Type
Technology offer
POD Reference
Term of Validity
26 March 2024 - 26 March 2025
Company's Country
Type of partnership
Research and development cooperation agreementCommercial agreement with technical assistance
Targeted Countries
All countries
Contact the EEN partner nearest to you for more information.
Find my local partner

General information

Short Summary
A Polish company from the biotechnology sector has developed a method of dealing with bacterial pathogens using bacteriophages - small agents that infect and kill bacteria. They are more precise, safer and more effective than commonly-used antibiotics - they even can deal with antibiotic-resistant strains of bacteria. Cooperation within the framework of a commercial agreement with technical assistance is offered or technical cooperation agreement.
Full Description
Bacteria are present in most of the Earth's habitats, frequently living in a symbiotic relationship with other organisms, benefiting humans, plants and animals. But not all bacteria are so helpful. Some can cause infectious diseases, thus changing the relationship into pathogenic and parasitic. The most common solution has been antibiotic. But they come with their own set of problems and side effects - most importantly they also kill the 'good' bacteria, thus destabilising organisms' natural microbiota. They also become increasingly ineffective due to a growing number of antibiotic-resistant strains of bacteria.

A biotech SME from the north-western part of Poland, which was founded in 2018 by two bioengineers with an academic background, has developed and is offering an alternative solution. They can neutralise harmful bacteria using submicroscopic infectious agents - bacteriophages. They replicate inside the living cells of bacteria and 'devour' them. The technology is more precise than antibiotics; one can use it to target one specific strain of bacteria instead of a broad spectrum of them, thus limiting side effects.

Medical applications of the technology have been widely known (phage therapy). But the company sees other fields it can be implemented e.g. agriculture and horticulture, animal husbandry, and veterinary medicine. With this goal in mind, the firm is offering commercial agreement with technical assistance to e.g. producers of agricultural chemicals, manufacturers of animal feed or other partners interested in adding or substituting currently used antibacterial agents with the offered bacteriophages.

The company is also open to collaboration with universities, R&D centres and other firms under the technical cooperation agreement on new products with antibacterial properties or new applications of bacteriophages. The company will contribute its technology, expertise and resources.
Advantages and Innovations
- although widely known, bacteriophages haven't been used in fields other than medicine;
- the offered solution is less harmful than antibiotics, as it has no side effects;
- the technology is more effective than antibiotics and can deal with antibiotic-resistant strains of bacteria;
- bacteriophages are more precise than antibiotics - the company can develop a mixture targeting specific bacteria that will combat strains a partner wants to kill;
- the company has a collection of over 900 phages with lytic potential and uses a neural network to create its highly-effective mixtures.
Stage of Development
Already on the market
Sustainable Development Goals
Not relevant

Partner Sought

Expected Role of a Partner
Commercial agreement:
Type: industry, i.e. manufacturers of animal feed, agricultural chemicals and other companies that want their products to have antibacterial properties.
Role: Partner will have to buy non-exclusive rights to the technology and introduce the bacteriophage mixture to its products.

Technical cooperation agreement:
Type: universities, R&D centres, companies
Role: Partner is expected to engage the company in its project aimed at developing new products with antibacterial properties or new applications of bacteriophages.
Type and Size of Partner
Big companySME 11-49R&D InstitutionSME 50 - 249SME <=10University
Type of partnership
Research and development cooperation agreementCommercial agreement with technical assistance

Call details

Coordinator required


Technology keywords
06001018 - Virus, Virology/Antibiotics/Bacteriology06002008 - Microbiology07001002 - Animal Production / Husbandry07002004 - Silviculture, Forestry08002002 - Food Microbiology / Toxicology / Quality Control
Market keywords
05008002 - Food and feed ingredients05009003 - Animal health08001022 - Agricultural chemicals09004008 - Other manufacturing (not elsewhere classified)
Targeted countries
All countries